Provided by Tiger Trade Technology Pte. Ltd.

Iterum Therapeutics Plc

0.3020
+0.01685.89%
Post-market: 0.30200.00000.00%19:07 EST
Volume:218.59K
Turnover:66.20K
Market Cap:15.94M
PE:-0.41
High:0.3158
Open:0.2955
Low:0.2900
Close:0.2852
52wk High:1.60
52wk Low:0.2600
Shares:52.79M
Float Shares:52.38M
Volume Ratio:0.41
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7366
EPS(LYR):-1.2576
ROE:-555.68%
ROA:-53.28%
PB:-2.16
PE(LYR):-0.24

Loading ...

Iterum Therapeutics plc Announces Date for Upcoming Extraordinary General Meeting of Shareholders

Reuters
·
Dec 24, 2025

Iterum Therapeutics Secures Major PBM Contract for ORLYNVAH Coverage

Reuters
·
Dec 23, 2025

BRIEF-Iterum Therapeutics Provides Business Update

Reuters
·
Dec 17, 2025

Iterum Therapeutics Announces Japanese Patent Office Decision to Grant Patent Covering Sulopenem Combination, Expiring in 2041

Reuters
·
Dec 17, 2025

Iterum Therapeutics Faces Nasdaq Delisting Risk Over Listing Rule Noncompliance

Reuters
·
Dec 13, 2025

BRIEF-Iterum Therapeutics Provides Business Update

Reuters
·
Dec 05, 2025

Iterum Therapeutics Plc - Rebate Agreement Signed With Top Medicare Part D Manager

THOMSON REUTERS
·
Dec 05, 2025

Director Michael W. Dunne Acquires Common Shares of Iterum Therapeutics plc

Reuters
·
Nov 20, 2025

Iterum Therapeutics Q3 Adjusted EPS USD -0.16

THOMSON REUTERS
·
Nov 14, 2025

Iterum Therapeutics Plc: Extends Cash Runway Into Q2 2026

THOMSON REUTERS
·
Nov 14, 2025

Press Release: Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Dow Jones
·
Nov 14, 2025

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More

Benzinga
·
Nov 10, 2025

Iterum Therapeutics PLC expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Maxim Group Sticks to Their Buy Rating for Iterum Therapeutics (ITRM)

TIPRANKS
·
Oct 02, 2025

Iterum Therapeutics sees cash runway into 2026

TIPRANKS
·
Sep 19, 2025

Iterum Therapeutics - Will Continue to Explore All Available Financing Opportunities to Extend Its Operating Runway

THOMSON REUTERS
·
Sep 19, 2025

Iterum Therapeutics plc Conducted Annual General Meeting

Reuters
·
Sep 11, 2025

Iterum Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule

Reuters
·
Aug 29, 2025

Iterum Therapeutics Launches Orlynvah™, the First and Only Oral Penem Antibiotic in the U.S.

THOMSON REUTERS
·
Aug 20, 2025

Michael W. Dunne, Director, Reports Acquisition of Common Shares of Iterum Therapeutics plc

Reuters
·
Aug 12, 2025